Novogene Europe has expanded its Cambridge Omics Centre with the launch of an untargeted metabolomics service, broadening its multiomics capabilities for researchers across the UK and Europe.

The new service is designed to complement the company’s existing genomics, transcriptomics, sequencing and bioinformatics offering by enabling researchers to incorporate metabolite-level analysis into studies exploring disease biology, microbiome interactions, biomarker discovery and treatment response.

Metabolomics examines the small molecules produced during biological processes, providing insight into the biochemical activity that links genetic information with observable biological function. By combining metabolomics with other omics technologies, researchers can build a more comprehensive understanding of complex biological systems.

The workflow is based on liquid chromatography-mass spectrometry using Thermo Scientific’s Vanquish ultra-high-performance liquid chromatography platform coupled with the Orbitrap Exploris 120 high-resolution mass spectrometer. According to Novogene Europe, the platform combines high-resolution metabolite profiling with an extensive reference library to support discovery-led research across a range of biological sample types.

Tingting Zhou, vice president of Novogene Europe, said: “Launching Untargeted Metabolomics through our Cambridge Omics Centre is an important step in strengthening Novogene Europe’s multiomics capabilities and supporting researchers with a more integrated view of biology.

“As research questions become more complex, customers increasingly need to connect genomic and transcriptomic information with functional biochemical insight. Metabolomics adds a powerful layer to this picture, helping researchers explore disease mechanisms, microbiome interactions, treatment response and pathway-level biology.”

The launch forms part of a broader expansion of capabilities at the Cambridge Omics Centre, located within the Bio-Innovation Centre. The facility supports academic, biotechnology and pharmaceutical researchers with sequencing, multiomics and bioinformatics services.

David Chaplin, general manager of the Bio-Innovation Centre, said: “Cambridge has a long-standing reputation as a centre for life science innovation, and access to advanced omics capabilities is an important part of that ecosystem.

“We welcome Novogene Europe’s continued investment in the Cambridge Omics Centre and its development of metabolomics services to support researchers and companies working at the forefront of biological discovery.”

Demand for integrated multiomics approaches has increased as researchers seek to combine genomic, transcriptomic and metabolic data to better understand disease mechanisms and identify potential therapeutic targets. Adding metabolomics to existing molecular analysis workflows allows investigators to study biological activity closer to phenotype, helping bridge the gap between genetic variation and cellular function.

The expansion strengthens Novogene Europe’s research services portfolio while reinforcing Cambridge’s position as one of Europe’s leading centres for life sciences research and technology development.